Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla ...

What is Zollinger-Ellison syndrome? Zollinger-Ellison syndrome (ZES) is a rare digestive disorder. If you have ZES, you likely have 1 or more tumors in the first part of the small intestine, the ...

AMG-329 is under clinical development by Amgen and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient ...

Amgen Inc. hasn't fared too well in recent months, as potential regulatory concerns take over. We cover some of the major sub-plots that could dominate the upcoming Q4 earnings event, due to take ...

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

The latest additions include weight-loss drugs Ozempic and Wegovy, as well as treatments inlcuding Trelegy Ellipta for asthma and Otezla for psoriatic arthritis. Several cancer medications are ...